Pharming Group (NASDAQ:PHAR) vs. Invivyd (NASDAQ:IVVD) Financial Survey

Pharming Group (NASDAQ:PHAR) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pharming Group and Invivyd, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0	2	3	0	2.60
Invivyd	1	1	3	0	2.40

Pharming Group currently has a consensus target price of $39.67, suggesting a potential upside of 206.31%. Invivyd has a consensus target price of $10.00, suggesting a potential upside of 1,662.74%. Given Invivyd’s higher possible upside, analysts plainly believe Invivyd is more favorable than Pharming Group.

Volatility and Risk

Pharming Group has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Pharming Group and Invivyd’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	6.23%	8.70%	4.93%
Invivyd	-183.90%	-59.73%	-48.97%

Insider & Institutional Ownership

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 12.2% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Pharming Group and Invivyd”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13 million	2.44	$2.85 million	$0.32	40.47
Invivyd	$53.43 million	3.13	-$52.49 million	($0.33)	-1.72

Pharming Group has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Summary

Pharming Group beats Invivyd on 7 of the 12 factors compared between the two stocks.

About Pharming Group

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

About Invivyd

Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.